An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.

Trial Profile

An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs PEG-haemoglobin carbon monoxide (Primary)
  • Indications Hypoxia
  • Focus Adverse reactions
  • Sponsors Prolong Pharmaceuticals
  • Most Recent Events

    • 09 Jan 2015 Last checked against ClinicalTrials.gov record.
    • 26 Oct 2013 New trial record
    • 03 Oct 2013 Results have been presented at the Joint Conference of the International Federation of Artificial Organs and the Japan Society of Artificial Organs according to a Prolong Pharmaceuticals media release. Results were also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top